Reward-based programs lead to higher rates of smoking cessation
the ONA take:
Reward-based lead to higher rates of sustained abstinence from smoking compared with deposit-based programs and group-oriented incentive programs are no more effective than individual-oriented programs, a new study published in The New England Journal of Medicine has shown.
For the study, researchers enrolled 2,538 CVS Caremark employees and their relatives and friends and randomly assigned them to one of four incentive programs or to usual care for smoking cessation.
Reward-based programs involved participants receiving about $800 for smoking cessation while the deposit-based programs entailed refundable deposits of $150 plus $650 in reward payments.
Results showed that rates of sustained abstinence from smoking through 6 months were higher in each of the incentive programs compared with usual care and the superiority of reward-based programs lasted through 12 months.
Researchers found that group-oriented and individual-oriented were associated with similar 6-month smoking cessation rates.
The study also showed that reward-based programs led to higher abstinence rates compared with deposit-based programs.
Reward-based lead to higher rates of sustained abstinence from smoking.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|